{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T04:30:00Z","timestamp":1772253000763,"version":"3.50.1"},"reference-count":34,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2022,5,3]],"date-time":"2022-05-03T00:00:00Z","timestamp":1651536000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>In Japan, healthcare workers (HCWs) are vaccinated against measles, rubella, chickenpox, mumps, and hepatitis B to prevent nosocomial infection; however, some do not produce sufficient antibodies (\u201csuboptimal responders\u201d). This study compared immune responses to a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 mRNA) vaccine among HCWs with normal and suboptimal responses to conventional vaccines. In this prospective cohort study, 50 HCWs received two doses of BNT162b2 mRNA vaccine 3 weeks apart. SARS-CoV-2 anti-spike antibodies were measured 11 times, starting before the first vaccination and ending 5 months after the second vaccination. Antibody titers of four suboptimal and 46 normal responders were compared. SARS-CoV-2 neutralizing antibody activity was measured twice in suboptimal responders, 1 week\/1 month and 5 months after the second vaccination. The SARS-CoV-2 anti-spike antibody was detectable in the samples from suboptimal and normal responders at each timepoint after vaccination. Suboptimal responders exhibited SARS-CoV-2 neutralizing antibody activity 1 week\/1 month as well as 5 months after the second vaccination; however, activity was slightly reduced at 5 months. Our findings show that suboptimal responders do acquire adequate SARS-CoV-2 anti-spike and SARS-CoV-2 neutralizing antibodies from vaccination to prevent SARS-CoV-2. SARS-CoV-2 mRNA vaccines should thus be recommended for both normal and suboptimal responders to conventional vaccines.<\/jats:p>","DOI":"10.3390\/v14050956","type":"journal-article","created":{"date-parts":[[2022,5,4]],"date-time":"2022-05-04T08:21:25Z","timestamp":1651652485000},"page":"956","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Can Individuals with Suboptimal Antibody Responses to Conventional Antiviral Vaccines Acquire Adequate Antibodies from SARS-CoV-2 mRNA Vaccination?"],"prefix":"10.3390","volume":"14","author":[{"given":"Wataru","family":"Ogura","sequence":"first","affiliation":[{"name":"Department of Clinical Laboratory, Kyorin University Hospital, Mitaka, Tokyo 181-8611, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kouki","family":"Ohtsuka","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Kyorin University School of Medicine, Mitaka, Tokyo 181-8611, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sachiko","family":"Matsuura","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, Kyorin University Hospital, Mitaka, Tokyo 181-8611, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Okuyama","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, Kyorin University Hospital, Mitaka, Tokyo 181-8611, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satsuki","family":"Matsushima","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Kyorin University School of Medicine, Mitaka, Tokyo 181-8611, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoko","family":"Yamasaki","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Kyorin University School of Medicine, Mitaka, Tokyo 181-8611, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Miyagi","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, Kyorin University Hospital, Mitaka, Tokyo 181-8611, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kumiko","family":"Sekiguchi","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, Kyorin University Hospital, Mitaka, Tokyo 181-8611, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Ohnishi","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Kyorin University School of Medicine, Mitaka, Tokyo 181-8611, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Kyorin University School of Medicine, Mitaka, Tokyo 181-8611, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,5,3]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Coronaviridae Study Group of the International Committee on Taxonomy of Viruses (2020). The species severe acute respiratory syndrome-related coronavirus: Classifying 2019-nCoV and naming it SARS-CoV-2. Nat. Microbiol., 5, 536\u2013544.","DOI":"10.1038\/s41564-020-0695-z"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41586-020-2008-3","article-title":"A new coronavirus associated with human respiratory disease in China","volume":"579","author":"Wu","year":"2020","journal-title":"Nature"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","article-title":"A pneumonia outbreak associated with a new coronavirus of probable bat origin","volume":"579","author":"Zhou","year":"2020","journal-title":"Nature"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa2001017","article-title":"A novel coronavirus from patients with pneumonia in China, 2019","volume":"382","author":"Zhu","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Song, Z., Xu, Y., Bao, L., Zhang, L., Yu, P., Qu, Y., Zhu, H., Zhao, W., Han, Y., and Qin, C. (2019). From SARS to MERS, Thrusting coronaviruses into the spotlight. Viruses, 11.","DOI":"10.3390\/v11010059"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1038\/emi.2012.1","article-title":"Receptor-binding domains of spike proteins of emerging or re-emerging viruses as targets for development of antiviral vaccines","volume":"1","author":"Jiang","year":"2012","journal-title":"Emerg. Microbes Infect."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(21)00947-8","article-title":"Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: An observational study using national surveillance data","volume":"397","author":"Haas","year":"2021","journal-title":"Lancet"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1056\/NEJMoa2101765","article-title":"BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting","volume":"384","author":"Dagan","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Papadopoli, R., De Sarro, C., Palleria, C., Gallelli, L., Pileggi, C., and De Sarro, G. (2021). Serological Response to SARS-CoV-2 Messenger RNA vaccine: Real-world evidence from Italian adult population. Vaccines, 9.","DOI":"10.3390\/vaccines9121494"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"100150","DOI":"10.1016\/j.lanepe.2021.100150","article-title":"Decreased infectivity following BNT162b2 vaccination: A prospective cohort study in Israel","volume":"7","author":"Amit","year":"2021","journal-title":"Lancet Reg. Health Eur."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Petter, E., Mor, O., Zuckerman, N., Oz-Levi, D., Younger, A., Aran, D., and Erlich, Y. (2021). Initial real world evidence for lower viral load of individuals who have been vaccinated by BNT162b2. MedRxiv.","DOI":"10.1101\/2021.02.08.21251329"},{"key":"ref_14","unstructured":"Pharmaceuticals and Medical Devices Agency (2022, February 20). Special Approval for Emergency on first COVID-19 vaccine in Japan [Media Release], Available online: https:\/\/www.pmda.go.jp\/english\/about-pmda\/0003.pdf."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1017\/S0950268813000393","article-title":"Seroprevalence survey on measles, mumps, rubella and varicella antibodies in healthcare workers in Japan: Sex, age, occupational-related differences and vaccine efficacy","volume":"142","author":"Kumakura","year":"2014","journal-title":"Epidemiol. Infect."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Ogawa, T., Inoue, T., Kasahara, K., Konishi, M., and Mikasa, K. (2020). Impact of vaccination on measles, mumps, and rubella antibody titers in Japanese healthcare workers: An observational study. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0230329"},{"key":"ref_17","unstructured":"(2020). Vaccine guidelines for medical personnel. Jpn. J. Infect. Prev. Control, 35, Available online: http:\/\/www.kankyokansen.org\/uploads\/uploads\/files\/jsipc\/vaccine-guideline_03(4).pdf."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"114271","DOI":"10.1016\/j.jviromet.2021.114271","article-title":"Performance evaluation of the Roche Elecsys anti-SARS-CoV-2 S immunoassay","volume":"297","author":"Riester","year":"2021","journal-title":"J. Virol. Methods"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3699","DOI":"10.1038\/s41596-020-0394-5","article-title":"Quantification of SARS-CoV-2 neutralizing antibody by a pseudotyped virus-based assay","volume":"15","author":"Nie","year":"2020","journal-title":"Nat. Protoc."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/s41586-020-03041-6","article-title":"Correlates of protection against SARS-CoV-2 in rhesus macaques","volume":"590","author":"McMahan","year":"2021","journal-title":"Nature"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transpl."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1126\/science.abg6105","article-title":"Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera","volume":"371","author":"Muik","year":"2021","journal-title":"Science"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1038\/s41586-020-2798-3","article-title":"SARS-CoV-2 vaccines in development","volume":"586","author":"Krammer","year":"2020","journal-title":"Nature"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1080\/21645515.2015.1093263","article-title":"Primary vaccine failure to routine vaccines: Why and what to do?","volume":"12","author":"Wiedermann","year":"2016","journal-title":"Hum. Vaccin. Immunother"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1111\/bjh.17918","article-title":"Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in haematopoietic stem cell transplantation recipients","volume":"196","author":"Yerushalmi","year":"2022","journal-title":"Br. J. Haematol."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Nomura, Y., Sawahata, M., Nakamura, Y., Kurihara, M., Koike, R., Katsube, O., Koike, R., Katsube, O., Hagiwara, K., and Niho, S. (2021). Age and smoking predict antibody titres at 3 months after the second dose of the BNT162b2 COVID-19 vaccine. Vaccines, 9.","DOI":"10.1101\/2021.08.06.21261590"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1002\/ajh.26284","article-title":"BNT162b2 COVID-19 vaccine is significantly less effective in patients with hematologic malignancies","volume":"96","author":"Gutwein","year":"2021","journal-title":"Am. J. Hematol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/S1470-2045(21)00213-8","article-title":"Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: Interim analysis of a prospective observational study","volume":"22","author":"Monin","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1038\/s41591-021-01542-z","article-title":"Immune responses to two and three doses of the BNT162b2 mRNA vaccine in adults with solid tumors","volume":"27","author":"Shroff","year":"2021","journal-title":"Nat. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1007\/s40264-021-01131-6","article-title":"COVID-19 vaccination in pregnancy, paediatrics, immunocompromised patients, and persons with history of allergy or prior SARS-CoV-2 infection: Overview of current recommendations and pre- and post-marketing evidence for vaccine efficacy and safety","volume":"44","author":"Luxi","year":"2021","journal-title":"Drug. Saf."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1753466620933508","DOI":"10.1177\/1753466620933508","article-title":"Lung under attack by COVID-19-induced cytokine storm: Pathogenic mechanisms and therapeutic implications","volume":"14","author":"Pelaia","year":"2020","journal-title":"Ther. Adv. Respir. Dis."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"3459","DOI":"10.2147\/IDR.S315727","article-title":"Overview of the main anti-SARS-CoV-2 vaccines: Mechanism of action, efficacy and safety","volume":"14","author":"Mascellino","year":"2021","journal-title":"Infect. Drug Resist."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e067873","DOI":"10.1136\/bmj-2021-067873","article-title":"Elapsed time since BNT162b2 vaccine and risk of SARS-CoV-2 infection: Test negative design study","volume":"375","author":"Israel","year":"2021","journal-title":"BMJ"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e84","DOI":"10.1056\/NEJMoa2114583","article-title":"Waning immune humoral response to BNT162b2 Covid-19 vaccine over 6 months","volume":"385","author":"Levin","year":"2021","journal-title":"N. Engl. J. Med."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/14\/5\/956\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:05:34Z","timestamp":1760137534000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/14\/5\/956"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,3]]},"references-count":34,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,5]]}},"alternative-id":["v14050956"],"URL":"https:\/\/doi.org\/10.3390\/v14050956","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.12.26.21268358","asserted-by":"object"}]},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,3]]}}}